At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed soft tissue sarcoma with progression to 1 or 2 prior chemotherapy regimens
- ✓Age greater than 19 and not exceeding 80 years at study entry
- ✓ECOG performance status 0 or 1
- ✓Measurable disease by RECIST v1.1
- ✕Excluded sarcoma subtypes: embryonal rhabdomyosarcoma, chondrosarcoma, osteosarcoma, Ewing tumors, primitive neuroectodermal tumor, gastrointestinal stromal tumor, dermatofibrosarcoma protuberans, inflammatory myofibroblastic sarcoma, liposarcoma
- ✕Prior treatment with PD-1, PD-L1, anti-PD-L2, CTLA-4, OX-40, CD137 inhibitors, or pazopanib
- ✕Unresolved toxicity NCI CTCAE Grade ≥2 from prior anticancer therapy
- ✕Major surgical procedure within 28 days before first dose
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pazopanib With or Without Pembrolizumab for Metastatic Soft Tissue Sarcoma: Open-label, Multicenter, Randomized, Phase 2 Trials
In Brief
A Phase 2 clinical trial evaluating pembrolizumab, pazopanib for Soft Tissue Sarcoma. Currently recruiting, targeting 116 participants across 1 site.
Detailed Summary
This is an open-label, randomized, phase II study to evaluate the clinical activity of pembrolizumab in combination with pazopanib compared to pazopanib monotherapy.
Study Details
Timeline
Interventions
Pembrolizumab will be given for a maximum of 2 years i.e. a total of 35 cycles of pembrolizumab with the q3 week dosing. Participants who complete study intervention after 2 years of pembrolizumab can be treated with pazopanib monotherapy based on physician's judgement. The duration of optional pembrolizumab crossover treatment will be maximum of 2 years i.e. a total of 35 cycles of pembrolizumab for patients progressing on pazopanib.